Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Borderline Resectable Pancreatic Carcinoma Clear all
Not listed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

NCT02839343
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Interventions
radiation therapy, surgery, mFOLFIRINOX, FOLFOX
Radiation · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
154
States / cities
Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT02243358
View directory record Official record
Conditions
Pancreas Neoplasm Malignant Resectable
Interventions
Folfox6, Gemcitabine, Radiation Therapy, Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
Drug · Radiation · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jun 25, 2026, 10:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

NCT01431794
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
LDE225-600mg, Gemcitabine, nab-paclitaxel, LDE225-400mg, LDE225-800mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

NCT01560949
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, 5-FU, Gemcitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jun 25, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

NCT02241551
View directory record Official record
Conditions
Borderline Resectable Pancreatic Cancer
Interventions
gemcitabine/nab-paclitaxel, mFOLFIRINOX
Drug
Lead sponsor
Nathan Bahary, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Results available

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

NCT03153410
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab, IMC-CS4
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Active, not recruiting Phase 1 Interventional

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

NCT04484909
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions
Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

NCT03970252
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Nivolumab, Oxaliplatin, Therapeutic Conventional Surgery
Drug · Biological · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jun 25, 2026, 10:47 AM EDT
Not listed Phase 2 Interventional Results available

FOLFIRINOX + RT for Pancreatic Cancer

NCT01591733
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Capecitabine, Short Course Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Jun 25, 2026, 10:47 AM EDT
Not listed Phase 2 Interventional

Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer

NCT01333332
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Standard Dose Acclerated Fraction Radiotherapy
Drug · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2011 · Synced Jun 25, 2026, 10:47 AM EDT
Withdrawn Phase 2 Interventional

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

NCT00728000
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, Oxaliplatin, Erlotinib
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

NCT02843945
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Directional Brachytherapy Source Implant
Device
Lead sponsor
CivaTech Oncology
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
6
States / cities
Tampa, Florida • Chicago, Illinois • Oak Lawn, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Not listed Phase 1 Interventional

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

NCT03703063
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, nab paclitaxel, Onivyde, Leucovorin, 5-fu
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

NCT01661088
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region

NCT02780648
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Stereotactic Body Radiation
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

NCT03704662
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting No phase listed Observational

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy

NCT06595160
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Not yet recruiting Phase 1 Interventional

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

NCT07645651
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 10:47 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

NCT03038477
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Durvalumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Jun 25, 2026, 10:47 AM EDT
Active, not recruiting Phase 2 Interventional

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

NCT04940286
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions
Durvalumab, Gemcitabine, Nab-paclitaxel, Oleclumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

NCT00761241
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy, Pancreaticoduodenectomy
Drug · Biological · Radiation + 1 more
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2010 · Synced Jun 25, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

NCT07043270
View directory record Official record
Conditions
Pancreas Adenocarcinoma
Interventions
Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 25, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

NCT03138720
View directory record Official record
Conditions
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
Interventions
Paclitaxel Protein Bound (Abraxane)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 25, 2026, 10:47 AM EDT
Not yet recruiting Not applicable Interventional

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

NCT07325214
View directory record Official record
Conditions
Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Interventions
IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
Device · Drug
Lead sponsor
IMGT Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jun 25, 2026, 10:47 AM EDT